Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2000

01-10-2000 | ORIGINAL ARTICLE

Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides

Authors: Brett W. Anderson, Andrezj P. Kudelka, Toshie Honda, Marilyn S. Pollack, David M. Gershenson, Michael A. Gillogly, James L. Murray, Constantin G. Ioannides

Published in: Cancer Immunology, Immunotherapy | Issue 9/2000

Login to get access
Metadata
Title
Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
Authors
Brett W. Anderson
Andrezj P. Kudelka
Toshie Honda
Marilyn S. Pollack
David M. Gershenson
Michael A. Gillogly
James L. Murray
Constantin G. Ioannides
Publication date
01-10-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000143

Other articles of this Issue 9/2000

Cancer Immunology, Immunotherapy 9/2000 Go to the issue

ORIGINAL ARTICLE

Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor

OriginalPaper

Erratum: Cancer Immunol Immunother (2000) 49: 314–318

ORIGINAL ARTICLE

Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines

ORIGINAL ARTICLE

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

ORIGINAL ARTICLE

Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas

ORIGINAL ARTICLE

Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits